Health
STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
Publication: STAT
Author: Andrew Joseph
Source published: 16/11/2026, 20:56:47 UTC
Briefing created: 22/11/2026, 09:05:13 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 13:51:25 UTC.
Briefings
The FDA approved Roche's giredestrant (Wilserdly) for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, extending time to tumor progression in the evERA trial. This marks a significant regulatory milestone for Roche, positioning it as a top-selling product, though the company has historically struggled in oncology compared to rivals like Genentech.
Key points
- The FDA approved giredestrant (Wilserdly) for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.
- The evERA trial demonstrated that the oral SERD drug extended the time period before patients' tumors progressed.
Context
Roche is launching giredestrant as its top-selling product ever, following the approval of Herceptin through Genentech. The approval provides a foothold in breast cancer treatments, though the company has historically fallen behind rivals in oncology.
Limitations
Evidence is limited to the FDA approval announcement and trial results; specific patient outcomes, long-term efficacy data, and real-world adoption rates are not detailed.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/11/2026, 09:05:13 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeieolx3snkky3jd4vvbrmr3ol6cwu2ywvnth26d3ln6sxwmgdgjii4